Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression
Cancer Letters · 2026-01 · 638 · 218160
DOI: 10.1016/j.canlet.2025.218160 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-01. Verfasst von Md Arafat Khan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA. Hauptthemen laut MEDLINE: Forkhead Box Protein M1, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, US Department of Defense, Breast Cancer Research Foundation.
Abstract (Originalsprache)
Small cell lung cancer (SCLC) is a lethal lung malignancy, which is associated with distant metastasis and chemoresistance. Due to the limited availability of targeted therapies, identifying a potential therapeutic target is a pressing unmet need in SCLC. Single-cell and bulk-transcriptomic datasets were analyzed that revealed FOXM1 as a potential targeting candidate in SCLC. High FOXM1 expression was observed in human and murine SCLC tissues and cell lines. Interestingly, chemoresistant (CR) SCLC cells exhibited substantially higher FOXM1 expression compared to naïve SCLC. Furthermore, FOXM1 inhibition in combination with platinum-based chemotherapy showed synergistic anticancer effects in vitro and in vivo xenograft and spontaneous (RPM: RB1fl/fl; TP53 fl/fl; LSL-MYCT58A) mouse models of SCLC. Mechanistically, RNA-seq analysis revealed that FOXM1 inhibition altered the Aurora Kinase B (AURKB) signaling pathway. Notably, FOXM1 inhibition enhanced T cell activation, supported differentiation of CD8+ T cells, and T cell-mediated killing of SCLC cells. Additionally, FOXM1 inhibition enhanced CD8+ T cell and macrophage recruitment in the tumor microenvironment (TME) of immunocompetent RPM model. This study demonstrates that FOXM1 targeting small molecule inhibitors (FOXM1i) has the potential to be a novel therapeutic strategy to combat SCLC progression, including chemotherapeutic resistance and reshaping the anti-tumor immune response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE-68198, USA. Electronic address: parvez.khan@unmc.edu.
- Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE-68198, USA.
- Department of Chemistry and Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
- Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
- Department of Molecular and Integrative Physiology and Cancer Center, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.
Förderung
- NCI NIH HHS
- US Department of Defense
- Breast Cancer Research Foundation
- National Cancer Institute
- National Institutes of Health
- Foundation for the National Institutes of Health
Zitieren
APA
Khan, M. A., Khan, P., Fatima, M., Rehman, A. U., Anwar, L., Alsafwani, Z. W., Ahmad, A., Abbas Zaidi, M. A., Cox, J. L., Zahid, A., Mohiuddin, S., Kim, S. H., Santamaria-Barria, J. A., Lakshmanan, I., Katzenellenbogen, B. S., Katzenellenbogen, J. A., Ganti, A. K., Batra, S. K., & Nasser, M. W. (2026). Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression. Cancer Letters, 638, 218160. https://doi.org/10.1016/j.canlet.2025.218160
Vancouver
Khan MA, Khan P, Fatima M, Rehman AU, Anwar L, Alsafwani ZW, et al. Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression. Cancer Letters. 2026;638:218160. doi:10.1016/j.canlet.2025.218160
BibTeX
@article{Khan2026,
author = {Khan, Md Arafat and Khan, Parvez and Fatima, Mahek and Rehman, Asad Ur and Anwar, Laiba and Alsafwani, Zahraa Wajih and Ahmad, Aatiya and Abbas Zaidi, Mohammad Ali and Cox, Jesse L and Zahid, Areem and Mohiuddin, Sameer and Kim, Sung Hoon and Santamaria-Barria, Juan A and Lakshmanan, Imayavaramban and Katzenellenbogen, Benita S and Katzenellenbogen, John A and Ganti, Apar K and Batra, Surinder K and Nasser, Mohd Wasim},
title = {Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression},
journal = {Cancer Letters},
year = {2026},
volume = {638},
pages = {218160},
doi = {10.1016/j.canlet.2025.218160}
}
EUVIMED